Search

Registration

Register here

The registration fee for the ESH-EBMT-EHA-IPIG 3rd Translational Research Conference: Bone Marrow Failure and Leukaemia Predisposition Syndromes is:
– 600€ for fully trained
– 300€ for in-training *
– 300€ Allied Health Professionals
– 600€ for Corporate
*A proof will be requested to confirm your status.…

Corporate Sponsor Program

View the EHA Ranking 2025

"Alone we can do so little; together we can do so much.

La Cantera coaching

Disease-orientated training courses for young clinicians and researchers, inspired by a world-renowned football academy model. Call for interest from SWGs
In 2025, EHA will fund an additional course based on the La Cantera model.

How to apply

The CRTH 2025 call for applications is now closed. Timelines
Application CRTH 2025
Deadline: September 24, 2024 (15:00 CEST)

Notification
November 2024

Questions: training@ehaweb. orgDownload the Signature letter template.

Adolescents and young adults (AYA)

Spotlight on AYAAdolescents and young adults (AYA) with hematologic diseases are a unique group with special characteristics and needs. In recent years, the challenges related to the management of AYA (particularly in relation to cancer) have increasingly been recognized.

Scientific Meetings

The EHA-SWG Scientific Meetings have been developed as a joint effort of the EHA Specialized Working Groups (SWGs) and EHA to intensify the beneficial collaboration.

Abstract & Clinical Case Submission and Travel Grant

Submit your abstract here

Abstract and clinical case procedurePlease note that the submission of an abstract constitutes a formal commitment by the presenting author to present the abstract (if accepted) orally or as a poster in the session at the time…

Abstract submission

Submit your abstract for a poster presentation here

Abstract procedurePlease note that the submission of an abstract constitutes a formal commitment by the presenting author to present the abstract (if accepted) orally or as a poster in the session at the…

I4MDS consortium: advancing MDS treatment and understanding

The role of the immune system in the pathophysiology of Myelodysplastic Neoplasms (MDS) is firmly established. However, routine immune monitoring for these patients is still not a common practice.